The role of obesity in the pathogenesis of benign prostatic hyperplasia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The pathophysiological role of obesity as one of the most significant and actual metabolic non-infectious diseases and the key component of the metabolic syndrome based on results of modern epidemiological and clinical-experimental studies is discussed in the review. General information on the prevalence of obesity and its negative effect on the quality oflife of men is presented. The endocrinology of adipose tissue and associated hormonal and metabolic disorders are discussed in more detail. The analysis of pathophysiological mechanisms explaining an influence of obesity on prostate metabolism, which leads to the initiation and progression of the benign prostatic hyperplasia, is carried out. Currently, there is a large body of evidence that obesity and benign prostatic hyperplasia have a lot of common interacting pathogenetic mechanisms. An opinion that, considering a global increase in the prevalence and severity of obesity in men and its negative effects on the prostate, treatment for obesity in men can be considered as an effective primary preventive measure, and in patients with benign prostatic hyperplasia as an effective secondary preventive measure.

Full Text

Restricted Access

About the authors

O. I Bratchikov

FGBOU VO “Kursk State Medical University”

Email: bratov45@mail.ru
MD, professor, Head of the Department of Urology

I. A Tyuzikov

Medical Center «Tandem-Plus»

Email: phoenix-67@list.ru

S. O Artishchev

FGBOU VO “Kursk State Medical University”

Email: sergey-artischev@yandex.ru

E. A Shumakova

FGBOU VO “Kursk State Medical University”

Email: ShumakovaEA1@kursksmu.net

References

  1. Lin H., Zhang L., Zheng R., Zheng Y. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant article. Medicine (Baltimore). 2017;96(47):e8838.
  2. E-source http: // www.10mkb.ru. Russian (Электронный ресурс http: // www.10mkb.ru).
  3. Муромцева Г.А. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012- 2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4-11
  4. Масленникова Г.Я., Бойцов С.А., Оганов Р.Г., Аксельрод С.В., Есин П.Е. Неинфекционные заболевания как глобальная проблема здравоохранения, роль ВОЗвее решении. Профилактическая медицина. 2015;1:9-13
  5. Mozaffarian D., Fahimi S., Singh G.M. et al. Global Burden of Diseases Nutrition and Chronic Diseases Expert Group. Global sodium consumption and death from cardiovascular causes. N Engl J Med. 2014;371(7):624-634
  6. James W.P.T., Jackson-Leach R., Mhurdu C.N. et al. Overweight and Obesity. In Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors: eds. Ezzati M, Lopez AD, Rodgers A, Murray CJL. WHO, Geneva, 2003.
  7. Ligibel J.A. et al. American Society of Clinical Oncology position statement on obesity and cancer. J. Clin. Oncol. 2014; 32(31): 3568-3574.
  8. World Health Organization Media Centre. Obesity and overweight. Fact sheet no Geneva: World Health Organization; 2013.
  9. Kramer C.K., Zinman B., Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and metaanalysis. Ann. Int. Med. 2013;159(11): 758-769.
  10. Jiao L. et al. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes & Control. 2010;21(8):1305-1314.
  11. Jungheim E.S. et al. Obesity and reproductive function. Obstetrics and gynecology clinics of North America. 2012;39(4):479-493.
  12. Шляхто Е.В., Недогода С.В., Конради А.О. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний (национальные клинические рекомендации). СПб., 2017. 164 с
  13. Калиниченко С.Ю., Тишова Ю.А., Тюзиков И.А., Ворслов Л.О. Ожирение и метаболический синдром у мужчин. М.: Практическая медицина, 2014. 128 с.
  14. Booth A., Magnuson A., Fouts J., Foster M.T. Adipose tissue: an endocrine organ playing a role in metabolic regulation. Horm Mol Biol Clin Investig. 2016;26(1):25-42.
  15. Coles C.A. Adipokines in Healthy Skeletal Muscle and Metabolic Disease. Adv Exp Med Biol. 2016;900:133-160.
  16. Luo L., Liu M. Adipose tissue in control of metabolism. J. Endocrinol. 2016;231(3):R77-R99.
  17. Villarroya F., Cereijo R., Villarroya J., Giralt M. Brown adipose tissue as a secretory organ. Nat Rev Endocrinol. 2017;13(1):26-35.
  18. Калинченко С.Ю., Тюзиков И.А., Ворслов Л.О., Тишова Ю.А., Греков Е.А., Фомин А.М. Ожирение (инсулинорезистентность) и бесплодие - две стороны одной медали: патогенетические взаимодействия и возможности современной фармакотерапии. Consilium Medicum. 2015;17(4):51-58
  19. Roncavi D.A.K., van R.L.R. Promotion of human adipocite precursor replication by 17 bestradiol in culture. J. Clin Invest 1977;62:503-508.
  20. Dobs A.S., Bachorik P.S., Arver S. et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J. Clin Endocrinol Metab 2001;86(3):1026-1033.
  21. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J. Clin Endocrinol Metab 2004;89(6):2548-2556.
  22. Калинченко С.Ю., Тюзиков И.А., Ворслов Л.О., Тишова Ю.А. Ожирение, инсулинорезистентность и репродуктивное здоровье мужчины: патогенетические взаимодействия и современная патогенетическая фармакотерапия. Эффективная фармакотерапия. Урология и нефрология. 2015;27: 66-79
  23. Mohler E.R. 3rd, Ellenberg S.S., Lewis C.E. et al. The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. J. Clin Endocrinol. Metab. 2018;103(2):681-688.
  24. Saad F. Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism). Adv Exp Med Biol. 2017;1043:527-558.
  25. Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О., Тишова Ю.А. Витамин D, мужское здоровье и мужская репродукция. Андрология и генитальная хирургия. 2013;4:36-44.
  26. Kalyani R.R., Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes. 2007;14(3):226-234.
  27. Schaffer J.E. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003;14(3):281-287.
  28. Irwin D.E., Milsom I., Hunskaar S. et al. Population Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study, 04 October 2006 Eur Urol. 2006;50(6):1306-1315.
  29. Kristal A.R., Arnold K.B., Schenk J.M. et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial J. Urol. 2007; 177: 1395-1400.
  30. Gacci M., Corona G., Vignozzi L., Salvi M., Serni S., De Nunzio C. et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analisys. BJU Int 2015;115(1):24-31.
  31. Kaplan S., Fisch H., Berriman S.J. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms, sexual dysfunction, and components of the metabolic syndrome J. Urol. 2007;177(Suppl):497-98.
  32. Cinar A., Hall S.A., Link C.L. et al. Cluster analysis and lower urinary tract symptoms in men: fi ndings from the Boston Area Community Health Survey. BJU Int. 2008;101:1247, 56.
  33. Desgrandchamps F., Haab F., Coloby P., Slama A., Gaudin A.F. Instant 2006: cardiometabolic markers in subjects with lower urinary tract symptoms in the French general population Eur Urol Suppl. 2008;7:130, Abstract 237.
  34. Kim G.W., Doo S.W., Yang W.J., Song Y.S. Effects of obesity on prostate volume and lower urinary tract symptoms in Korean men. Korean J. Urol. 2010;51:344-347.
  35. Chu K.F., Rotker K., Ellsworth P. The impact of obesity on benign and malignant urological conditions. Postgrad Med. 2013;125(4):53-69.
  36. Lee R.K., Chung D., Chughtai B., Te A.E., Kaplan S.A. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms BJU. 2012;110(4): 540-545.
  37. Parsons J.K., Sarma A.V., Mc Vary K., Wei J.T. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J. Urol 2009;182 (6 suppl):27-31.
  38. Pashootan P., Ploussard G., Cocaul Лю, Gouvello Лю, Desgrandchamps F. Association between metabolic syndrome and severity lower urinary tract symptoms (LUTS): an observation study in a 4666 European men cohort. BJU Int 2015;116(1):124-130.
  39. Ксенева С.И., Юрмазов З.А., Удут В.В. Влияние немедикаментозной коррекции метаболического синдрома на состояние предстательной железы у пациентов молодого возраста. Евразийский союз ученых. 2016;2- 2(23):64-66
  40. Khoo J., Piantadosi C., Worthley S., Wittert G.A. Effects of a low-energy diet on sexual function and lower urinarytract symptoms in obese men. Int J. Obes 2010;34:1396-1403.
  41. Parsons J.K., Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. EurUrol 2008;53:1228-1235.
  42. Jung J.H., Ahn S.V., Song J.M. et al. Obesity as a Risk Factor for Prostatic Enlargement: A Retrospective Cohort Study in Korea. Int Neurourol J. 2016;20(4):321-328.
  43. Zhang X., Zong X., Liu Y. et al. Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol. Int. 2014;93:214-219.
  44. Dahle S.E., Chokkalingam A.P., Gao Y.T. et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J. Urol 2002;168(2):599-604.
  45. Fong Y.K., Milani S., Djavan B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol. 2005;15(1): 5-38.
  46. Ganpule A.P., Desai M.R., Desai M.M. Natural history of lower urinary tract symptoms: Preliminary report from a community-based Indian study. BJU Int. 2004;94:332-334.
  47. Patel N.D., Parsons J.K. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J. Urol. 2014;30(2): 170-176.
  48. Tyagi P., Motley S.S., Koyama T. et al. Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients. Prostate. 2018;78(1):17-24.
  49. Расин М.С. Хроническое воспаление и инсулинорезистентность в патогенезе доброкачественной гиперплазии предстательной железы. Экспериментальная и клиническая урология. 2016;1: 52-56
  50. Bastard J.-P., Maachi M., Lagathu C. et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006;17(1):4-12.
  51. De Nunzio C., Kramer G., Marberger M. et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur. Urol. 2011;60(1):106-117.
  52. De Nunzio C., Aronson W., Freedland S.J. et al. The correlation between metabolic syndrome and prostatic diseases. Eur. Urol. 2012;61(3): 560-570.
  53. Shenk J.M., Kristal A.P., Neuhouser M.L. et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am. J. Epidemiol. 2010;171(5):571-582.
  54. Gacci M., Vignozzi L., Sebastianelli A. et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 2013;16(1):101-106.
  55. He Q., Wang Z., Liu G. et al. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational risks. Prostate Cancer Prostatic Dis 2016; 19(1):7-13.
  56. Ozer K., Horsanali M.O., Gorgel S.N. et al. Association between benign prostatic hyperplasia and neutrophil-lymphocyte ratio, an indicator of inflammation and metabolic syndrome. Urol. Int. 2016.
  57. Vignozzi L., Gacci M., Cellai I. et al. Fat boost, while androgene receptor activation counteracts BPH-associated prostate inflammation. Prostate. 2013;73(8):789-800.
  58. Robert G., Descazeaud A., Nicolaiew N. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate. 2009;69:1774-1780.
  59. Rohrmann S., De Marzo A.M., Smith E. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;62:27-33.
  60. Penna G., Fibbi B., Amuchastegui S. The vitamin D. receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009;69:480-493.
  61. Fibbi B., Penna G., Morelli A. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int. J. Androl. 2010;33:475-488.
  62. Protopsaltis I., Ploumidis A., Sergentanis T.N., Constantoulakis P., Tzirogiannis K., Kyprianidou C. et al. Linking pre-diabetes with benign prostatic hyperplasia. IGFBP-3: a conductor of benign prostatic hyperplasia development orchestra? PloS One. 2013;8(12):e81411.
  63. Cantiello F., Cicione A., Salonia A. et al. Metabolic syndrome correlates with peri-urethral fibrosis secondary to chronic prostate inflammation: evidence of a link in a cohort of patients undergoing radical prostatectomy. Int J. Urol. 2014; 21(3): 264-269.
  64. Morelli A., Comeglio P., Filippi S. et al. Mechanism of action of phosphodiesterase 5 inhibition on metabolic syndrome-associated prostate alteration: an experimental study in the rabbit. Prostate 2013;73(4): 428-441.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies